Kleerekoper M
Department of Internal Medicine, Saint Joseph Mercy Hospital, Ann Arbor, MI, USA.
Osteoporos Int. 2006 Dec;17(12):1707-15. doi: 10.1007/s00198-006-0187-x. Epub 2006 Aug 15.
While bone mineral density measurements play a central role in osteoporosis management, the degree to which increases in this parameter contribute to bone fragility, fracture risk, and the therapeutic efficacy of osteoporosis agents is controversial. Indeed, bone strength is also significantly dependent upon bone turnover and bone quality, including microarchitecture, mineralization, and geometry. Given the critical role of these factors, it is essential to understand how they are affected by therapeutic agents. Even though a number of technological advances, such as microcomputed tomography, magnetic resonance imaging, and computerized analysis of radiographic patterns, help to provide critical information toward a more comprehensive assessment of bone turnover and bone quality, clinical trials addressing these factors are scarce. This article provides a review of studies relating to how osteoporosis therapies impact parameters of bone strength and quality.
虽然骨密度测量在骨质疏松症管理中起着核心作用，但该参数的增加对骨脆性、骨折风险以及骨质疏松症药物治疗效果的影响程度存在争议。事实上，骨强度还显著依赖于骨转换和骨质量，包括微观结构、矿化和几何形状。鉴于这些因素的关键作用，了解它们如何受到治疗药物的影响至关重要。尽管一些技术进步，如微型计算机断层扫描、磁共振成像和放射影像模式的计算机分析，有助于提供关键信息以更全面地评估骨转换和骨质量，但针对这些因素的临床试验却很稀少。本文综述了有关骨质疏松症治疗如何影响骨强度和质量参数的研究。
